- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Senate passes Drug Quality and Security Act
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug designed to treat asthma in children.
Watson Pharmaceuticals announced Wednesday the approval of budesonide inhalation suspension in the 0.25-mg/2-mL and 0.5-mg/2-mL strengths. The drug is used to control and prevent asthma symptoms in children ages 12 months to 8 years.
The drug is a generic version of AstraZeneca's Pulmicort Respules, which had sales of $1.1 billion during the 12-month period ended in May.